Abstract Library

#2948 Efficacy Prediction Using Computed Tomography for Patients with Pancreatic Neuroendocrine Tumors Receiving Sunitinib

Introduction: How to predict the efficacy of sunitinib before treatment initiation was less known.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zhang Y, Chen L, Wang W, Jin K, Yuan B,

Keywords: sunitinib, computed tomography, efficacy prediction,

#2730 FOLFIRINEC, A Multi-Center, Randomized, Comparative Phase II Study of FOLFIRINOX vs Platinum-Etoposide as First Line Treatment for Metastatic Neuroendocrine Carcinoma of Gastroenteropancreatic or Unknown Origin, Associated with Molecular Profiling

Introduction: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine carcinoma (NEC) are rare diseases with a poor prognosis. FOLFIRINEC is a multicenter comparative phase II study of mFOLFIRINOX vs platinum-etoposide (PE) as first line treatment for metastatic G3 NEC of GEP or unknown origin.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hadoux J

Authors: Hadoux J, Afchain P, Walter T, Tougeron D, Hautefeuille V,

Keywords: neuroendocrine carcinoma, gastroenteropancreatic, chemotherapy, FOLFIRINOX, RB,

#2214 The Trend of Using CT to Diagnose the Gastroenteropancreatic Neuroendocrine Neoplasms: Results of a Nation-Wide Retrospective Epidemiology Study in China

Introduction: Representative data on the gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) in Asian patients is rare, especially in China.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Fan J, Yu P, Chi Y, Shi S, Chen Y,

Keywords: gastroenteropancreatic neuroendocrine neoplasms, CT, combined examinations,

#2211 Clinicopathologic Characteristics of Chinese Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: Results of a Nation-Wide Retrospective Epidemiology Study

Introduction: he rare incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) has contributed to a paucity of large epidemiologic studies of patients with this condition, especially in China.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Yu P, Chi Y, Shi S, Chen Y, Jiang L,

Keywords: gastroenteropancreatic neuroendocrine neoplasms, clinicopathological characteristics, immunohistochemical staining,

#2167 Evaluation of Streptozocin-Based Chemotherapeutic Regimens for Advanced Pancreatic Neuroendocrine Tumors: A Multi-Center Clinical Study in Japan

Introduction: Streptozocin (STZ) has been used as a key drug against advanced pancreatic neuroendocrine tumors (pNETs). The standard in many countries is a daily STZ regimen combined with 5-fluorouracil administered once daily for 5 days every 6 weeks. However, in Japan, STZ was only covered by insurance beginning in 2015, and STZ is often used as monotherapy, as either a daily or a weekly regimen. There are few reports on STZ monotherapy for pNETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Sakamoto Y, Hijioka S, Shibuya H, Ito T, Imamura M,

Keywords: Streptozocin, pNETs,